Slide 1: Corporate Presentation
Corporate Presentation August 2026
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Harrow. We Are Ophthalmic Pharma.
Harrow. We Are Ophthalmic Pharma. Diversified provider of ophthalmic disease management solutions in North America Key revenue drivers are best- Scalable commercial platform; Largest U.S. portfolio of prescription ophthalmic in-class products with large innovative approach to products, broadly cover
Slide 4: Harrow. We Are Ophthalmic Pharma.
Harrow. We Are Ophthalmic Pharma. 4 Corporate Presentation | August 2026
Slide 5: Investment Highlights
Investment Highlights Key revenue drivers in growth mode; revenue catalysts through 2029 Dry Eye Disease Ocular Anesthesia 21% TRx growth Q2 ’26 vs Q1 ‘26 44% Unit demand growth Q2 ’26 vs Q1 ‘26 • Outpaced branded DED market growth during Q2 (21% vs. 14%) • Highest unit demand quarter since launch •
Slide 6: Durable Growth: Launches & Pipeline
Durable Growth: Launches & Pipeline Launching at least one product every year through 2029 – within Harrow’s existing cost structure and commercial footprint YOCHIL Clobetasol Topical Steroid Anti-VEGF Biosimilar Midazolam ODT Series Q3 2026 2027 2028 1 2 3 4 5 6 2H 2026 2028 H2 2028 / H1 2029 G-MEL
Slide 7: Financials & Outlook
Financials & Outlook 2Q26 | Results and Outlook Key Financial Metrics and Revenue Conversion 7 Corporate Presentation | August 2026
Slide 8: Key Financial Metrics
Key Financial Metrics Five years of consistent revenue and EBITDA expansion Q2 2026 Key Metrics FIVE-YEAR TRACK RECORD Q2 2026 Key Metrics CONSOL IDATED REV ENUE REVENUE ADJ. EBITDA $ in millions 41% 5-Yr CAGR $70.7M $(1.2)M $400M $357.5M (Midpoint) $300M $272.3M PR ODU CT REVENUE $199.6M $200M $88.
Slide 9: H1-H2 2026: Converting Demand to Revenue
H1-H2 2026: Converting Demand to Revenue Q2's +60% sequential revenue growth came with five key levers still switched off — all five are now live in H2 2026 H1 2026 · BUILDING DEMAND H2 2026 · CONVERTING TO REVENUE +60% $44.2M → $70.7M Q1 to Q2 2026 revenue +39–45% $114.9M → $235–250M H1 to H2 reven
Slide 10: Dry Eye Disease
Dry Eye Disease VEVYE | TYRVAYA | Harrow’s Dry Eye Portfolio Market Leadership, Growth and Differentiation 10 Corporate Presentation | August 2026
Slide 11: Building the Leading Dry Eye Portfolio
Building the Leading Dry Eye Portfolio VEVYE remains our first-line therapy for chronic dry eye disease. By adding TYRVAYA, along with other ocular surface treatments in the Harrow portfolio, like FRESHKOTE® and FLAREX®, we can now provide prescribers with a more complete approach to treating DED us
Slide 12: VEVYE — Best-in-Class for DED
VEVYE — Best-in-Class for DED The first and only water-free cyclosporine for the signs and symptoms of dry eye disease MARKET OP PORT UNIT Y DED Patient Funnel ~22x More cyclosporine delivered into the cornea vs. Restasis Preclinical ex-vivo corneal penetration study data 38M+ Americans with dry eye
Slide 13: VEVYE Q2 2026 Key Metrics
VEVYE Q2 2026 Key Metrics +40% ~4% ~21% +15% 14.6% Revenue Growth NRx Growth TRx Growth Prescriber Growth Market Share Q2 '26 vs Q1 '26 Q2 '26 vs Q1 '26 Q2 ’26 vs Q1 ‘26 Q2 '26 vs Q1 '26 As of end of June ‘26 Quarterly Revenue Q2 Highlights U.S. net revenue | Q2 ‘25 → Q2 ‘26 • Outpaced branded Dry E
Slide 14: TYRVAYA — Differentiated Treatment
TYRVAYA — Differentiated Treatment The only FDA-approved nasal spray for DED — stimulating natural tear production through a different pathway than drops THE MECHANISM ZERO Contraindications · Ocular AEs · Label Warnings • Selective nicotinic receptor agonist — activates the trigeminal pathway to st
Slide 15: Full Spectrum Leadership
Full Spectrum Leadership Harrow fields products engineered to win – on efficacy, patient experience, and economics 01 CHRONIC 02 EPISODIC 03 EPISODIC 04 EPISODIC Anti-Inflammatory Basal Tear Production Tear Film Stabilization Steroids Chronic inflammatory DED — the seminal Aqueous-deficient DED — dr
Slide 16: Ocular Anesthesia
Ocular Anesthesia IHEEZO | In-Office Ocular Surface Anesthesia Market Opportunity, Clinical Profile, and Access 16 Corporate Presentation | August 2026
Slide 17: IHEEZO Overview
IHEEZO Overview • First-in-class: only branded ocular anesthetic approved in the U.S. in nearly 14 years 1 Sterile, single-patient-use, physician-administered, • Large TAM: >14M annual U.S. ocular procedures require surface anesthesia2 ophthalmic gel preparation for • Reimbursement unlocked: permane
Slide 18: IHEEZO Total Addressable Market
IHEEZO Total Addressable Market All eight procedure categories are IHEEZO-applicable | CPT codes shown with each procedure Estimated Annual U.S. Procedure Volume (millions) Intravitreal Injections 67028 10.0M Laser Procedures 65855 / 66761 / 67210 1.5M Gonioscopy (Procedural) 92020 1.0M Foreign Body
Slide 19: IHEEZO Q2 2026 Key Metrics
IHEEZO Q2 2026 Key Metrics Record unit demand, ordering accounts and re-order rate | Net pricing up ~25% effective Q3 2026 +44% +32% 85.5% ~25% Unit Demand Growth Total Ordering Accounts Re-Order Rate Increase in Net Pricing Q2 ‘26 vs Q1 ‘26 224 total · 62 first-time in Q2 Trailing 12 months Effecti
Slide 20: Injectables
Injectables TRIESENCE | Ophthalmic Injectable Portfolio Market Opportunity and Commercial Update 20 Corporate Presentation | August 2026
Slide 21: TRIESENCE Overview
TRIESENCE Overview Injectable suspension (triamcinolone acetonide 40 mg/mL) with separate reimbursement in every Commercial Expansion into traditional care setting1 Ocular Inflammation Regulatory Only FDA-approved preservative-free synthetic corticosteroid for injectable ophthalmic use 7M+ Annual po
Slide 22: TRIESENCE Q2 2026 Key Metrics
TRIESENCE Q2 2026 Key Metrics +39% 54% Volume from Ocular Surgery +69 7Qs Unit volume growth Net new accounts QoQ Consecutive growth Accounts Q2 ‘26 vs Q1 ‘26 Q2 ‘26 805 total accounts – highest since launch Since re-launch Quarterly unit demand +162% YoY Q2 Hig hlig hts Unit demand per quarter | Q1
Slide 23: Anti-VEGFs
Anti-VEGFs BYOOVIZ | OPUVIZ | Ophthalmic Biosimilars Market Opportunity and Differentiated Approach 23 Corporate Presentation | August 2026
Slide 24: Best-in-Class Anti-VEGF Biosimilars
Best-in-Class Anti-VEGF Biosimilars Two FDA-approved ophthalmic biosimilars acquired from Samsung Bioepis — addressing the largest market in ophthalmology REFERENCED DRUG First FDA-approved LUCENTIS® referenced biosimilar FDA-approved EYLEA® referenced biosimilar ● Neovascular (Wet) Age-Related Macu
Slide 25: Anti-VEGF Market
Anti-VEGF Market A defined market opportunity met with a differentiated, relationship-led commercial strategy U.S. Anti-VEGF Market Harrow's Differentiated Launch Strategy ~8.5M units annually | >$4.2B Medicare Part B spend Account-Level Retina Relationships • Years of trusted service to retina prac
Slide 26: Specialty and Access+
Specialty and Access+ VERKAZIA | NATACYN | Specialty Portfolio Steroids, NSAIDs and Anti-Inflammatories 26 Corporate Presentation | August 2026
Slide 27: Specialty and Access+
Specialty and Access+ Eleven branded ophthalmic products + ImprimisRx compounded formulations Q2 2026 HIGHLIGHTS STEROIDS ANTIHISTAMINE — — • IOPIDINE J-Code effective July 1, NSAIDs ANTIBIOTIC improving reimbursement and supporting — — commercial adoption ANTI- STEROID INFLAMMATORIES COMBINATION •
Slide 28: IOPIDINE Enabled by Reimbursement
IOPIDINE® Enabled by Reimbursement Only FDA-approved therapy to prevent procedural IOP spikes CLI NI CA L EVID ENCE MARKET OPPORTUNITY Indication Only FDA-approved product to prevent IOP spikes after certain in-office laser procedures 1.5M+ ~91% J-Code ~91% risk reduction Annual U.S. Relative risk E
Slide 29: The VERKAZIA Opportunity
The VERKAZIA® Opportunity VKC is a chronic allergic eye disease — driven by immune dysregulation, across a spectrum (from highly underdiagnosed mild cases to severe and sight-threatening cases), which primarily affects children, but can reach into adulthood THE DISEASE SPECTRUM WHY IT MATTER S — THE
Slide 30: The NATACYN Opportunity
The NATACYN® Opportunity Blepharitis is not a single infection — it is a microbiome imbalance (or dysbiosis) of the eyelid margin, driven by multiple etiologic pathogens THE ETIOLOGIC TRIAD WHY IT MATTER S — THE CLINICAL GAP FUNGUS ON ~50% ~79% Demodex Mite: 300 – 400 micrometers (µm)2 Fungus (Hypha
Slide 31: MELT Programs
MELT Programs G-MELT | YOCHIL | Sedation Pipeline Non-IV, Opioid-Free Sedation Programs in Development 31 Corporate Presentation | August 2026
Slide 32: G-MELT: IV & Opioid-Free Sedation
G-MELT: IV & Opioid-Free Sedation Fixed dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid), two known and proven FDA- approved molecules in a novel form WHAT MAKES G-MELT DIFFERENT PATH TO L AUN CH Zydis® sublingual technology Dissolves in seconds under the tongue. Exclusi
Slide 33: YOCHIL: Pediatric Oral Midazolam ODT
YOCHIL: Pediatric Oral Midazolam ODT Oral dissolving tablet delivering midazolam for sedation, anxiolysis, and amnesia prior to diagnostic, therapeutic, or endoscopic procedures in pediatric patients WHAT MAKES YOCHIL DIFFERENT De-risked clinical pathway PATH TO L AUN CH Extensive clinical dataset g
Slide 34: References
References Sources and footnotes for figures cited throughout this presentation Data sources Product comparisons Market, prescription, and procedure data are drawn from IQVIA Product comparisons are for illustrative purposes only. No head-to- (including Xponent), PhilRx, Vestrum Health, Market Scope